Navigation Links
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
Date:2/18/2009

ABBOTT PARK, Ill., and WATERTOWN, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration with a first-in-human study evaluating ABT-450, an oral protease inhibitor for the treatment of chronic HCV. The objectives of the trial include assessment of safety, tolerability and pharmacokinetics. ABT-450 was discovered as part of a worldwide alliance between Abbott and Enanta to discover, develop and commercialize protease inhibitors for the treatment of HCV.

"Hepatitis C is a serious global health concern, with 170 million people currently infected by six different HCV genotypes," said John M. Leonard, M.D., senior vice president, Global Pharmaceutical Research and Development, Abbott. "As a global leader in the development of antiviral therapies and diagnostics, Abbott is bringing its decades of antiviral experience, particularly with protease inhibitors, to this collaboration and to the fight against HCV."

"ABT-450 demonstrated favorable potency in vitro across various HCV genotypes and highly resistant strains," said Jay R. Luly, Ph.D., president and CEO of Enanta Pharmaceuticals. "We look forward to working with Abbott to advance ABT-450, and to our building a pipeline of HCV protease inhibitors that addresses this widespread disease."

Phase 1 Study Design

The Phase 1, double-blind, placebo-controlled study for ABT-450 announced today is a single, ascending oral dose trial in healthy volunteers.

About the Hepatitis C Virus

Hepatitis C is a liver disease affecting more than 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death.

Liver disease associated with HCV infection is growing rapidly, and current therapies only provide sustained benefit in about half of patients with the genotype 1 form of the virus. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best-in- class small molecule drugs in the anti-infective field. Enanta is developing novel protease, polymerase and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at http://www.enanta.com.

About Abbott

Abbott is working to advance the treatment of Hepatitis C (HCV) through a multifaceted discovery and development program that leverages the company's deep experience in antiviral medicines. Compounds in various states of development include protease inhibitors (ABT-450) and polymerase inhibitors (ABT-333 and ABT-072). In addition to developing HCV therapies, Abbott also offers laboratory tests for patient diagnosis, blood screening tests for hospitals and blood banks, and molecular diagnostic tests to measure HCV viral load and resistance.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott; Enanta Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
2. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
3. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
4. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
5. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
6. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
7. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
8. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
9. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
Breaking Medicine News(10 mins):